Scott Millman, MD PhD
@ScottMillmanMD
Followers
82
Following
39
Media
0
Statuses
7
Medical Oncologist and Leukemia Researcher at MSKCC. Tweets are my own.
Joined January 2020
RT @ktsanov: 18 years ago, I came to the US to pursue my dream of becoming a scientist. Last week marked a major milestone in this journey,….
0
44
0
RT @MSK_DeptOfMed: Congrats to Eytan Stein, MD, and team on the publication of their study in @Nature demonstrating that the menin inhibito….
mskcc.org
Based on a clinical trial led by an MSK investigator, the FDA has approved revumenib (Revuforj®) for patients one year and older who have leukemia that has come back after treatment and whose cancer...
0
12
0
RT @Lingbo_Zhang: Thrilled to share new review of Zhang Lab @CSHL "Metabolism in acute myeloid leukemia: mechanistic insights & therapeutic….
0
5
0
Powerful genetic engineering strategy to study cancer from @MSKCancerCenter named for @officialDannyT's MACHETE.
During my postdoc I embarked on understanding this biology and developed MACHETE, a deletion engineering strategy! We uncover that loss of 9p21.3 affects immune surveillance by disrupting both CDKN2A/B and a cluster of linked type I interferons.
0
1
15
RT @LoweLabMSKCC: New Preprint! Led by #DynamicDuo @BarrigaFM & @KTsanov, this study set out to understand how somatic copy number alterati….
biorxiv.org
Somatic chromosomal deletions are prevalent in cancer, yet their functional contributions remain ill-defined. Among the most prominent of these events are deletions of chromosome 9p21.3, which...
0
48
0